L&C BIO Co.,LTD (KOSDAQ:290650)
55,200
+600 (1.10%)
Nov 20, 2025, 3:30 PM KST
L&C BIO Co.,LTD Revenue
L&C BIO Co.,LTD had revenue of 20.58B KRW in the quarter ending June 30, 2025, with 15.38% growth. This brings the company's revenue in the last twelve months to 75.98B, up 10.10% year-over-year. In the year 2024, L&C BIO Co.,LTD had annual revenue of 72.09B with 9.35% growth.
Revenue (ttm)
75.98B
Revenue Growth
+10.10%
P/S Ratio
17.69
Revenue / Employee
535.05M
Employees
142
Market Cap
1.34T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 72.09B | 6.17B | 9.35% |
| Dec 31, 2023 | 65.93B | 13.35B | 25.40% |
| Dec 31, 2022 | 52.57B | 6.90B | 15.10% |
| Dec 31, 2021 | 45.68B | 12.70B | 38.53% |
| Dec 31, 2020 | 32.97B | 3.82B | 13.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 620.28B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |